@Consul, I have the same concerns as you, that the ME/CFS research community's interest in Dr Markov's theory and treatment of ME/CFS may grow only slowly, and assuming the treatment does indeed work, it will be some time before there are replication studies, and some time before we see the take up of this treatment in other countries.
As you say, Dr Markov's autovaccine treatment is lengthy, and so even for ME/CFS patients like
@Hipsman who started the treatment in June 2021, it's will be 2 to 3 years before we know the full results. Although we should have a good sense of whether it is working after about a year of treatment.
@Hipsman already feels that his PEM has improved a little, though he says it is hard to tell.
This is one of my motivations for trying to become a autovaccine guinea pig, so that we might at least have some anecdotal accounts of how the treatment went 2 or 3 years from now. If we can open up the possibility of remote treatment at the Markov Clinic, we may find some more ME/CFS patients become interested in trying this treatment.
Do you know which ME/CFS researchers have spoken to Dr Igor Markov?
I sent a volley of emails to a dozen or so ME/CFS researchers who I thought might be interested in Dr Markov's theory and treatment, especially researchers with an interest in bacterial, leaky gut and LPS etiologies of ME/CFS. Only the
Morten Group in Oxford replied to my email and showed some interest.
The Morten Group by the way are doing lots of interesting ME/CFS research on a low budget (detailed in
this presentation), and I hope they manage to secure more funding, because there are not many good ME/CFS research groups in the UK.
Unfortunately ME/CFS research does go far more slowly than we would like. If we look at the rituximab research, for example, which was the great hope of the ME/CFS community for many years, the very first paper published by Fluge and Mella was in 2009, and their final phase III clinical trial was published ten years later in 2019 (and unfortunately showed rituximab was not generally beneficial for ME/CFS). So that rituximab saga took a full ten years from beginning to end.